Mobility Limitation: Clinical Trials

7 trials for Mobility Limitation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 7
Phase 11Completed 1
Phase 31Completed 1

Follow Mobility Limitation: new trials by email Literature Review of Mobility Limitation trials Research Report on Mobility Limitation

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Heat Therapy, Functional Capacity, and Vascular Health in Older Adults
Home-based leg heat therapy, Home-based sham therapy - Aging Well, Walking, Difficulty
Phase 1 / Phase 2CompletedUniversity of North Texas Health Science Center212022-11-032026-06-05
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Parts A/B: Adrabetadex, Parts A/B: Sham Control - Niemann-Pick Disease, Type C
Phase 2 / Phase 3CompletedMandos LLC562015-10-012023-02-22
Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty
denosumab - Osteoarthritis, Hip, Ambulation Difficulty
Phase 2CompletedHans Mallmin642012-08-072017-04-05
Experimental Control Investigation of the Impact of Assistive Technology on the User-caregiver Dyad: a Multi-site Trial
Assistive technology updating and tune up intervention - Mobility Limitations
Phase 2CompletedCentre de Recherche de l'Institut Universitaire de Geriatrie de Montreal882009-06-012014-02-19
Effects of Game-based Balance Exercise for Older Adults With Fall History
game-based balance exercises - Mobility Limitation
Phase 2CompletedUniversity of Manitoba302007-08-012011-06-27
Restoring Skill in Walking
gait intervention - Mobility Limitation
Phase 2CompletedUniversity of Pittsburgh482005-11-012007-12-13
Increasing Physical Activity Among Overweight Women With Mobility Disabilities.
Personalized exercise programme (PEP) - Obesity
Phase 2CompletedCenters for Disease Control and Prevention962004-10-012019-07-26

Narrower conditions

Cognitive Dysfunction (1)  ·  Deglutition Disorders (1)  ·  Disease (1)  ·  Hyperemia (1)  ·  Hyperthermia (1)  ·  Motor Activity (1)  ·  Niemann-Pick Disease, Type C (1)  ·  Obesity (1)  ·  Osteoarthritis, Hip (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (7)  ·  Signs and Symptoms (7)  ·  Nutritional and Metabolic Diseases (2)  ·  Arthritis (1)  ·  Behavior (1)  ·  Body Temperature Changes (1)  ·  Body Weight (1)  ·  Brain Diseases (1)  ·  Brain Diseases, Metabolic (1)  ·  Brain Diseases, Metabolic, Inborn (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Cognition Disorders (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Digestive System Diseases (1)

Interventions

2-Hydroxypropyl-beta-cyclodextrin (1)  ·  Cyclodextrins (1)  ·  Denosumab (1)

Sponsors

Centers for Disease Control and Prevention (1)  ·  Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal (1)  ·  Hans Mallmin (1)  ·  Mandos LLC (1)  ·  University of Manitoba (1)  ·  University of North Texas Health Science Center (1)  ·  University of Pittsburgh (1)

Countries

United States (4)  ·  Canada (2)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  New Zealand (1)  ·  Singapore (1)  ·  Spain (1)  ·  Sweden (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Top investigators

Hans Mallmin, MD, PhD (1)  ·  James Rimmer, Ph.D. (1)  ·  Jessie VanSwearingen, PhD, PT (1)  ·  Louise Demers, PhD (1)  ·  Nils Hailer, MD, PhD (1)  ·  Tony Szturm, BSc(PT), PhD (1)

Results publications

PMID 19459233, PMID 21799138, PMID 22003158, PMID 31589776, PMID 40525490, PMID 40584156, PMID 41921101

NIH funding

2015 (1)